The AHA Aug. 28 urged the Drug Enforcement Administration to reconsider its proposed 2019 aggregate production quotas for certain controlled substances, which the agency said would reduce manufacturing quotas for six frequently misused opioids by an average 10 percent. “Hospitals and other providers are currently facing critical shortages of a number of injectable opioid medications for which that the DEA recommends quota reductions, including morphine, hydromorphone, and fentanyl,” AHA said in a letter to DEA. “These decreases would exacerbate these already dire shortages.” AHA said its request is “specific to these injectable medopications and does not extend to other dosage forms or opioid products.” Comments are due Sept. 19.

Related News Articles

Headline
The Health Resources and Services Administration yesterday awarded 80 rural consortia $1 million each to help prevent, treat and support recovery for patients…
Headline
The National Association of Attorneys General yesterday urged congressional leaders to remove federal barriers to opioid use disorder treatment.
Headline
The number of naloxone prescriptions dispensed from retail pharmacies doubled in 2018, but access to the emergency opioid overdose treatment still varies…
Headline
The Department of Health and Human Services seeks input from health care providers and other stakeholders for a report to Congress on ensuring legitimate…
Headline
The Department of Health and Human Services yesterday sent Congress its plan to help states develop and expand innovative strategies to provide housing-related…
Headline
Qualified nonprofits and government agencies may submit through Aug. 25 letters of intent to apply for funding from the Foundation for Opioid Response Efforts…